Understanding an Increasingly Complex Treatment Landscape in Urothelial Carcinoma: Guidance for Frontline Oncology Practitioners

How are you incorporating new treatment options into your clinical practice for patients with urothelial cancer?

Elizabeth R. Plimack, MD, MS Released: September 15, 2020

Download this PDF clinical resource on toxicity management to help optimize the care of your patients with progressive urothelial carcinoma receiving erdafitinib or enfortumab vedotin.

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Released: November 5, 2020

Download this PDF patient safety guide for a quick resource on signs and symptoms of specific AEs patients should look for while they are receiving erdafitinib or enfortumab vedotin.

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Released: January 6, 2021

Download this PDF clinical resource for an overview on treatment options for your patients with advanced urothelial carcinoma, highlighting recently approved agents.

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Released: January 7, 2021

Review slides with commentary in slidenotes from pharmacist and nursing experts on patient counseling, monitoring, and managing adverse events associated with avelumab, enfortumab vedotin, and erdafitinib in urothelial carcinoma.

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Released: January 11, 2021

Listen as Kinjal Patel, PharmD, BCOP, discusses the most recent data on new treatment options for patients with advanced or metastatic urothelial carcinoma.

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 13, 2020 Expired: November 12, 2021

Kinjal Patel, PharmD, BCOP, discusses the mechanism of action, indication and treatment considerations when using enfortumab vedotin for patients with advanced or metastatic urothelial carcinoma.

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Pharmacists: 0.25 contact hours (0.025 CEUs) Registered Nurses: 0.25 Nursing contact hours Released: December 16, 2020 Expired: December 15, 2021

Kinjal Patel, PharmD, BCOP, discusses the mechanism of action, indication, and treatment considerations when using erdafitinib for patients with advanced or metastatic urothelial carcinoma.

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 1, 2020 Expired: November 30, 2021

Review important nursing considerations and tips for educating patients undergoing treatment with erdafitinib or enfortumab vedotin for advanced urothelial carcinoma.

Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 30, 2020 Expired: November 29, 2021

Listen as Susan K. Roethke, CRNP, MSN, AOCNP, ANP-BC, discusses optimal management of common AEs associated with enfortumab vedotin treatment in patients with advanced or metastatic urothelial carcinoma.

Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 22, 2020 Expired: December 21, 2021

Listen as Susan K. Roethke, CRNP, MSN, AOCNP, ANP-BC, discusses optimal management of common AEs associated with erdafitinib treatment in patients with advanced or metastatic urothelial carcinoma.

Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 21, 2020 Expired: December 20, 2021